Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of December 2023, specifically dated December 13, 2023. The report serves to furnish a press release regarding clinical study results for the Company's ProSense® technology in the context of breast cancer treatment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is the release of new clinical study findings. The study indicates that cryoablation using Icecure's ProSense® technology allows for the ultimate de-escalation of surgical therapy for select breast cancer patients. No financial changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The press release incorporates "Forward Looking Statements" by reference into the Company's Registration Statements on Form F-3 and Form S-8. The filing does not provide specific numerical guidance or detailed risk factors within the text of the Form 6-K itself, deferring to the incorporated press release for such details.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific study data and patient outcomes.
- Review the "Forward Looking Statements" section within the press release for associated risks and assumptions.
- Confirm the status of the Company's Registration Statements (Form F-3 and Form S-8) where these statements are incorporated.
- Check subsequent filings for any updates on the commercialization or regulatory status of the ProSense® technology.